Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19.
J Cell Mol Med
; 25(1): 591-595, 2021 01.
Article
in English
| MEDLINE | ID: covidwho-934013
ABSTRACT
COVID-19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral-induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID-19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
COVID-19
/
COVID-19 Drug Treatment
/
Analgesics, Opioid
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Cell Mol Med
Journal subject:
Molecular Biology
Year:
2021
Document Type:
Article
Affiliation country:
Jcmm.15927
Similar
MEDLINE
...
LILACS
LIS